Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merlin L Robb

Showing results (231-240 of 358) with videos related to

Pageof 36
Sort By:
Journal of Virology|July 14, 2017
Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine RegimenAsli Bauer, Lilli Podola, Philipp Mann, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2017
High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV InfectionCari F Kessing, Serena Spudich, Victor Valcour, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 27, 2018
Noninfectious Comorbidity in the African Cohort StudyJulie A Ake, Christina S Polyak, Trevor A Crowell, et al.
AIDS Research and Human Retroviruses|August 4, 2015
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine RegimensNicos Karasavvas, Chitraporn Karnasuta, Hathairat Savadsuk, et al.
Plos Pathogens|March 18, 2022
HIV-1 infections with multiple founders associate with the development of neutralization breadthEric Lewitus, Samantha M Townsley, Yifan Li, et al.
Plos One|October 29, 2014
CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participantsKalpana Dommaraju, Gustavo Kijak, Jonathan M Carlson, et al.
The Journal of Clinical Investigation|September 15, 2022
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 monthsMagdalena E Sobieszczyk, Jill Maaske, Ann R Falsey, et al.
The Journal of Infectious Diseases|January 19, 2010
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)Hannah Kibuuka, Robert Kimutai, Leonard Maboko, et al.
Journal of Virology|February 2, 2018
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among VaccineesNicole L Yates, Allan C deCamp, Bette T Korber, et al.
Plos One|November 30, 2018
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial designEdna O Viegas, Arne Kroidl, Patricia J Munseri, et al.
Pageof 36

Showing results (231-240 of 358) with videos related to

Sort By:
Pageof 36
Journal of Virology|July 14, 2017
Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine RegimenAsli Bauer, Lilli Podola, Philipp Mann, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2017
High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV InfectionCari F Kessing, Serena Spudich, Victor Valcour, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 27, 2018
Noninfectious Comorbidity in the African Cohort StudyJulie A Ake, Christina S Polyak, Trevor A Crowell, et al.
AIDS Research and Human Retroviruses|August 4, 2015
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine RegimensNicos Karasavvas, Chitraporn Karnasuta, Hathairat Savadsuk, et al.
Plos Pathogens|March 18, 2022
HIV-1 infections with multiple founders associate with the development of neutralization breadthEric Lewitus, Samantha M Townsley, Yifan Li, et al.
Plos One|October 29, 2014
CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participantsKalpana Dommaraju, Gustavo Kijak, Jonathan M Carlson, et al.
The Journal of Clinical Investigation|September 15, 2022
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 monthsMagdalena E Sobieszczyk, Jill Maaske, Ann R Falsey, et al.
The Journal of Infectious Diseases|January 19, 2010
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)Hannah Kibuuka, Robert Kimutai, Leonard Maboko, et al.
Journal of Virology|February 2, 2018
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among VaccineesNicole L Yates, Allan C deCamp, Bette T Korber, et al.
Plos One|November 30, 2018
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial designEdna O Viegas, Arne Kroidl, Patricia J Munseri, et al.
Pageof 36